Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
Association for the Treatment of Sexual Abusers of sexual abuse through effective treatment and management of sex offenders. It has approximately 3,000 members from 26 countries, with chapters throughout the United States and in Utrecht, Netherlands. Members include researchers, treatment providers, corrections officials, attorneys, law enforcement officers, and students. ATSA hosts the world's largest annual conference and leading educational venue for individuals working on issues related to the research, treatment, and management of sexual abuse. Conference locations vary each year. The official journal of ATSA is "Sexual Abuse", produced eight times a year. According to the Institute for Scientific Information, the peer-reviewed journal's 2016 impact factor was